Results 231 to 240 of about 1,452,954 (261)

Producing Bispecific and Bifunctional Antibodies

2004
Bispecific antibodies are artificially engineered monoclonal antibodies (MAbs) that consist of two distinct binding sites and are capable of binding two different antigens noncovalently. They can be produced by chemical cross-linkage, genetic engineering, or somatic hybridization.
Mavanur R. Suresh, Dipankar Das
openaire   +3 more sources

Bispecific Antibody Therapy in Hemophilia

New England Journal of Medicine, 2017
Hemophilia A is the most common severe inherited bleeding disorder in humans. Bleeding occurs as a result of a deficiency or dysfunction of the procoagulant cofactor protein, factor VIII. For the past 50 years, the treatment and prevention of bleeding in hemophilia A has involved the intravenous infusion of plasma-derived or recombinant factor VIII ...
openaire   +3 more sources

Introduction: bispecific antibodies

Journal of Immunological Methods, 2001
George J. Weiner, Louis M. Weiner, David M. Segal   +2 more
openaire   +3 more sources

Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies

2019
Bispecific antibodies are an emerging novel therapeutic construct used to treat a variety of cancers. These drugs utilize a small fusion protein to link two single-chain antibodies, allowing for simultaneous binding of two different epitopes. Bispecific T-cell engagers (BiTE) are a subset of bispecific antibodies that bind the target antigen on the ...
Stacy Cooper, Patrick A. Brown
openaire   +2 more sources

Bispecific antibodies in myeloma

Hématologie, 2021
Sophie Le Grand, Aurore Perrot
openaire   +1 more source

Bispecific antibody therapy for lymphoma

Best Practice & Research Clinical Haematology
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL.
Genevieve M, Gerhard, Gottfried, von Keudell   +1 more
openaire   +2 more sources

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Javier Cortés, Giuseppe Curigliano, Paolo Tarantino   +2 more
exaly  

Current treatment and future directions in the management of anal cancer

Ca-A Cancer Journal for Clinicians, 2022
Leila T Tchelebi, Cathy Eng, Craig A Messick   +2 more
exaly  

Modern developments in germline pharmacogenomics for oncology prescribing

Ca-A Cancer Journal for Clinicians, 2022
Natalie M Reizine, Peter H O'donnell
exaly  

Immunotherapy with bispecific antibodies.

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 1995
With rare exceptions, monoclonal antibodies as therapeutic agents for cancer, have had limited anti-tumor effects. Attempts to improve the cytotoxicity of antibodies by using them as guiding agents for immune effector cells, have been developed. Numerous in vitro studies have shown that T lymphocytes can be targeted towards any target cell by using ...
openaire   +2 more sources